BioStem Technologies (BSEM) director gains 5,647 shares from RSUs
Rhea-AI Filing Summary
BioStem Technologies, Inc. (BSEM) director Jodi Ungrodt reported the vesting and exercise of restricted stock units into common stock. On August 27, 2026, 5,647 restricted stock units, each representing a contingent right to one common share, were converted into 5,647 shares of common stock. Following this transaction, Ungrodt directly held 11,295 shares of common stock and no remaining restricted stock units from this grant, which had vested in two installments on May 27, 2026 and August 27, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 5,647 shares
Net Buy
2 txns
Insider
UNGRODT JODI
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units F1, F2 | 5,647 | $0.00 | $0.00 |
| Exercise | Common Stock | 5,647 | $0.00 | $0.00 |
Holdings After Transaction:
Restricted Stock Units — 0 shares (Direct);
Common Stock — 11,295 shares (Direct)
Footnotes (2)
- F1. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- F2. These restricted stock units vest in two installments. The first installment vested on May 27, 2026, and the remaining installment vested on August 27, 2026.
Key Figures
Restricted stock units exercised: 5,647 units
Common shares acquired via RSU conversion: 5,647 shares
Common shares held after transaction: 11,295 shares
+2 more
5 metrics
Restricted stock units exercised
5,647 units
Restricted Stock Units converted into common stock on August 27, 2026
Common shares acquired via RSU conversion
5,647 shares
Common Stock received upon RSU exercise on August 27, 2026
Common shares held after transaction
11,295 shares
Direct ownership after August 27, 2026 transaction
RSU transaction price per share
$0.00 per share
Reported exercise price for RSU conversion on August 27, 2026
RSU vesting dates
May 27, 2026 and August 27, 2026
Two-installment vesting schedule for these restricted stock units
Key Terms
Restricted Stock Units, contingent right, vest, Exercise or conversion of derivative security
4 terms
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
contingent right financial
"represents a contingent right to receive one share of the issuer's common"
vest financial
"These restricted stock units vest in two installments"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
Exercise or conversion of derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
FAQ
What insider transaction did BSEM director Jodi Ungrodt report on August 27, 2026?
Ungrodt reported the vesting and exercise of 5,647 restricted stock units into 5,647 shares of BioStem Technologies, Inc. common stock on August 27, 2026, as part of an equity award that vested in two installments.
What happened to Jodi Ungrodt’s restricted stock units in BSEM reported in this filing?
The filing shows 5,647 restricted stock units were exercised and converted into 5,647 common shares. The units from this grant vested in two installments, on May 27, 2026 and August 27, 2026, leaving no units from this award after conversion.
Were the BSEM restricted stock units granted to Jodi Ungrodt tied to common stock?
Yes. Each restricted stock unit represented a contingent right to receive one share of BioStem Technologies, Inc. common stock, according to the footnote in the Form 4.
Does this BSEM Form 4 show a market purchase or sale by Jodi Ungrodt?
No market purchase or sale is shown. The Form 4 reports a code M exercise/conversion of 5,647 restricted stock units into 5,647 shares, with a reported transaction price of $0.00 per share for the exercise.
AI-generated analysis. How Rhea-AI works. Not financial advice.
